BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 25342504)

  • 1. Metastatic nasopharyngeal carcinoma outcomes in patients on cisplatin with nolatrexed or 5-fluorouracil.
    Zheng J; Lin J; Wang L; Zhou J; Xie B; Xu T; Zhang W
    Oncol Res Treat; 2014; 37(10):540-4. PubMed ID: 25342504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy.
    Gao Y; Huang HQ; Bai B; Cai QC; Wang XX; Cai QQ
    Expert Opin Pharmacother; 2014 Feb; 15(2):163-71. PubMed ID: 24295173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma.
    Chen C; Wang FH; An X; Luo HY; Wang ZQ; Liang Y; Zhang L; Li YH
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):371-8. PubMed ID: 23143190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.
    Hong RL; Sheen TS; Ko JY; Hsu MM; Wang CC; Ting LL
    Br J Cancer; 1999 Aug; 80(12):1962-7. PubMed ID: 10471046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma.
    Xue C; Huang Y; Huang PY; Yu QT; Pan JJ; Liu LZ; Song XQ; Lin SJ; Wu JX; Zhang JW; Zhao HY; Xu F; Liu JL; Hu ZH; Zhao LP; Zhao YY; Wu X; Zhang J; Ma YX; Zhang L
    Ann Oncol; 2013 Apr; 24(4):1055-61. PubMed ID: 23172635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of responses and prognostic factors in different chemotherapy regimens for metastatic nasopharyngeal carcinoma: a report of 171 cases].
    Zhou J; Zhang WM; Chen H; Xie B; Zheng JH; Xu ZY; Lin JR
    Zhonghua Zhong Liu Za Zhi; 2009 Nov; 31(11):867-72. PubMed ID: 20137355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy.
    Peng PJ; Ou XQ; Chen ZB; Liao H; Peng YL; Wang SY; Zhang HY; Lin Z
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):323-8. PubMed ID: 23728706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery.
    Wang Y; Wang ZQ; Jiang YX; Wang FH; Luo HY; Liang Y; Wang DS; Li YH
    Expert Opin Pharmacother; 2016 Aug; 17(12):1585-90. PubMed ID: 27328125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
    Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
    Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study.
    Hong S; Zhang Y; Yu G; Peng P; Peng J; Jia J; Wu X; Huang Y; Yang Y; Lin Q; Xi X; Xu M; Chen D; Lu X; Wang R; Cao X; Chen X; Lin Z; Xiong J; Lin Q; Xie C; Li Z; Pan J; Li J; Wu S; Lian Y; Yang Q; Zhao C; Fang W; Zhang L
    J Clin Oncol; 2021 Oct; 39(29):3273-3282. PubMed ID: 34379443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of efficacy of docetaxel combined cisplatin (TP regimen) and cisplatin combined 5-fluorouracil (PF regimen) on locally advanced nasopharyngeal carcinoma].
    Xie FY; Qi SN; Hu WH; Zou GR; Peng M; Li JS
    Ai Zheng; 2007 Aug; 26(8):880-4. PubMed ID: 17697552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outpatient weekly 24-hour infusional adjuvant chemotherapy of cisplatin, 5-fluorouracil, and leucovorin for high-risk nasopharyngeal carcinoma.
    Lin JC; Jan JS; Chen KY; Hsu CY; Liang WM; Wang WY
    Head Neck; 2003 Jun; 25(6):438-50. PubMed ID: 12784235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent Chemoradiotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) in Patients with Nasopharyngeal Carcinoma.
    Komatsu M; Arai Y; Yabuki K; Sano D; Shiono O; Sakuma Y; Nishimura G; Takahashi M; Taguchi T; Oridate N
    Anticancer Res; 2015 Dec; 35(12):6861-7. PubMed ID: 26637908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials.
    Lee AW; Tung SY; Ngan RK; Chappell R; Chua DT; Lu TX; Siu L; Tan T; Chan LK; Ng WT; Leung TW; Fu YT; Au GK; Zhao C; O'Sullivan B; Tan EH; Lau WH
    Eur J Cancer; 2011 Mar; 47(5):656-66. PubMed ID: 21112774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy regimens containing taxanes or fluorouracil in nasopharyngeal carcinoma: Which better?
    Mi JL; Zhang B; Pan YF; Su YX; Fan JF; Liao SF; Qin XL; Yao DC; Tang HY; Jiang W
    Oral Oncol; 2017 Nov; 74():34-39. PubMed ID: 29103749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma.
    Li YH; Wang FH; Jiang WQ; Xiang XJ; Deng YM; Hu GQ; Xu DM; Chen Y; Lin Q; He YJ
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):539-44. PubMed ID: 18172651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma.
    Huang Y; Liang W; Yang Y; Zhao L; Zhao H; Wu X; Zhao Y; Zhang Y; Zhang L
    BMC Cancer; 2016 Jul; 16():464. PubMed ID: 27411683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents.
    Casanova M; Özyar E; Patte C; Orbach D; Ferrari A; Veyrat-Follet C; Errihani H; Pan J; Zhang L; Shen L; Grzegorzewski KJ; Varan A
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):289-98. PubMed ID: 26666649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
    Chen X; Liang W; Wan N; Zhang L; Yang Y; Jiang J; Zhang T
    Oral Oncol; 2019 Jul; 94():80-85. PubMed ID: 31178217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Induction chemotherapy with docetaxel plus cisplatin (TP regimen) followed by concurrent chemoradiotherapy with TP regimen versus cisplatin in treating locally advanced nasopharyngeal carcinoma].
    Xie FY; Zou GR; Hu WH; Qi SN; Peng M; Li JS
    Ai Zheng; 2009 Mar; 28(3):279-85. PubMed ID: 19619443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.